



SANA PHARMA

A fast-growing company focused on the development, registration, manufacturing, and marketing of pharmaceutical products with outstanding quality directed to unmet therapeutic needs. Sana Pharma started its pharmaceutical service activities in 2007 with, product development, contract analysis, and regulatory consultation.

The company was established by a group of qualified professionals having extensive knowledge and experience in research and development in the pharmaceutical industry, in close cooperation with academic experts.

Sana Pharma's core values are to produce innovative health solutions for the community either in the form of quality pharmaceutical products or by licensing products to other pharmaceutical companies.



Ahmad Hajjaj Str., Shafa Badran Industrial Area, Amman-Jordan
Tel. : +962 6 5233349, Fax.: +962 65233744
Info@sana-pharma.com www.sana-pharma.com

www.sana-pharma.com




PREMISES

- 01 cGMP manufacturing site for medical devices & medicated cosmetics.
- 02 cGMP manufacturing site for semisolid medicinal products.
- 03 cGMP manufacturing site for solid dosage form medicinal products.
- 04 cGMP manufacturing site for herbal extract.
- 05 CE mark issued for several products of Sana.

01 In 2015-2016 Sana Pharma was successfully accessing the new emerging markets using different business models, such as branded finished product supply, private label and technology transfer projects.

02 Sana Pharma drew its position in pharmaceutical field through its ability to understand the markets. It has developed an internal processes that explores market needs, pharmaceutical trends and translates the project ideas on the ground by developing and introducing new products in different markets in a disciplined manner.

03 Sana Pharma is recognized as one of the fastest growing companies in the region in 2011 & 2012 (All world network and Harvard business school classification).



SANA PHARMA WORLD PRESENCE

- Iraq
- Saudi Arabia
- Romania
- Russia
- Tunisia
- Libya
- Algeria
- Morocco
- Sudan
- Yemen
- UAE
- Egypt
- Palestine
- Lebanon
- Qatar
- Canada

CE MARK




- StoPain Plus
- Lialec
- Scarmed
- TGC plus
- Lectoine



Sana Pharma
Innovative health solutions

OUR STORY



CERTIFICATES



ISO/IEC 17025
(international accreditation of Laboratories)



ISO 13485 (For exporting medical device products to Europe)



ISO 9001



GMP certified manufacturing site of semisolid dosage form



GMP certified manufacturing site of solid dosage




Cosmetics-Good manufacturing practice (GMP)



PUBLICATIONS

The research company CRD (Sana group), has successfully filed two PCT patents at the US patent office.



Novel fixed dose triple therapy for resistant hypertension.

HER3 receptor targeted therapy in cancer (Novel MAB for cancer).

Sana Pharma has many scientific contributions, the following are some articles published in international journals :

Solubility of Diclofenac sodium, effect off additive. A comparative study with Diclofenac Diethylamine, Drug development & industrial pharmacy.

The use of Drug excipient in designing and evaluation of TDDS, under publication.

Spectroscopic and HPLC methods for determination of Alendronate in tablets and urine, Talanta 64(2004)695-702.

Olanzapine Inhibits Glycogen Synthase Kinase-3 β : An Investigation by Docking Simulation and Experimental Validation, European Journal of pharmacology.

Sustained release suspension of antiepileptic for pediatric applications", patent under filing in cooperation with a group of researchers, faculty of pharmacy, UJ.

Modulation of Buspirone HCl release from hypromellose matrices using chitosan succinate: Implication for pH-independent release. European journal of pharmaceuticals and biopharmaceuticals (2008).

Novel HPLC method for determination of Sitosterols in herbal products, under publication.

Determination of Primeverin and Primulaverin in cough syrup containing Primula root extract, under publication.

Cosmeceutical Formulations of Pro-Vitamin E Phosphate: In-vitro Release Testing and Dermal Penetration into Excised Human Skin, in cooperation with a group of researchers, International Journal of Pharmaceutics.


The Potential Use of Inhaled Hydroxychloroquine for the Treatment of COVID-19 in Cancer Patients, in cooperation with KHCC.

LICENSING OUT BUSINESS

Sana Pharma developed a pipeline of medicinal products and licensed it to leading Pharmaceutical companies in MENA and EU.



SISTER COMPANIES



BASIC ACHIEVEMENTS



Successful technology transfer projects of the pharmaceutical pipeline to more than 24 countries. The transferred products contribute with more than 150 million of sales for our customers.



Licensing potential and niche products to the biggest generic pharmaceutical companies in the middle east.



Registering and marketing the first oral antiviral product for COVID-19;
Favipiravir under the brand of Sancovir

Sana pharma is one of the first pharmaceutical companies who adapted the strategy of VAM (value added medicine).



Comprehensive pipeline of branded generics developed and registered based on market needs, most of them introduced to the market as first generic or differentiated or VAM



SANA DURING COVID PANDEMIC

SANA PHARMA RECOGNIZES ITS DUTY TO SUPPORT THE COUNTRY AND PEOPLE DURING THE COVID 19 PANDEMIC AND AS PART OF ITS CORPORATE SOCIAL RESPONSIBILITY THE COMPANY IS:

- ▶▶ Granting the right for companies and agencies to manufacture it's sanitizing and disinfecting products, such as Sanagel, free of charge to help meet the products' growing demand during the pandemic.
Taking part in the government's awareness campaigns on COVID-19 safety measures, by using the company's social media platforms.
Disinfecting the governmental buildings and establishments.
- ▶▶ Donating Sancovir (Favipiravir) to the goverment and healthcare professionals with confirmed COVID-19 cases.



SANA PHARMA

is the first company in the Middle East to introduce a pipeline of innovative hygienic products such as hand sanitizers, surface disinfectants, and air disinfectants applying new technologies and novel ingredients.

The pipeline includes:

- ▶▶ Sanaseptic: A long acting surface disinfectant based on Quaternary Ammonium compound attached to a self adhesive polymer.
- ▶▶ Sana AHP: An accelerated Hydrogen Peroxide solution that is effective at low concentration due to synergistic effect with other additives.

Making the product effective as hand sanitizer, surface disinfectant and air disinfectant.

SanaGuard: A hand moisturizing Alcohol lotion.



**EVIDENCE BASED
MEDICINE**

Sana Pharma holds highly the importance of clinical trials and continuous testing for its products in order to provide solid evidence for their safety and efficacy.

“The impact of pharmaceutical care on the efficacy and safety of transdermal glucosamine sulfate and capsaicin for joint pain” is the latest published article for the product **TGC plus**.



LICENSING IN BUSINESS

SANA PHARMA ESTABLISHED STRATEGIC BUSINESS RELATIONS WITH DRUG LICENSORS AND SUCCESSFULLY REGISTERED AND MARKETED THEIR PRODUCTS IN THE REGION.

LICENSOR LIST INCLUDES



BIOCAD
Biotechnology Company

*Biocad (Russia):
for biological
and biosimilar*



*Saiph (Tunisia):
for injectable
(general category)*



*Macleod (India):
for certain
generic products*

Main products:

- Bevasan (Bevacizumab)
- Hertisan (Trastuzumab)
- Ruxera (Rituximab)
- D-Rise inject (vitamin D3 injection -100.000, 200.000, 300.000 IU)
- B12 injection

Sana Pharma

1 The fastest-growing pharmaceutical company in Jordan

2 One of the top three Biological companies in Jordan

3 Has a very strong network of sales and marketing in MENA region

4 One of the main players in tender business and hospital supply in Jordan specially for biologicals

5 Has two affiliated factories in KSA and Iraq, and also market authorization company in Switzerland


6 Has four medical teams in Jordan for different specialties including for tender

7 Has the strongest antidiabetic drugs and onco-biological drugs pipeline in Jordan

SALES GROWTH



*For the past four years,
Sana Pharma's sales have been
growing at such an impressive level*



PRODUCTS REGISTRATION

Sana Pharma
Innovative health solutions

Sana Pharma portfolio is rich of registered products in different categories, with active pipeline continuously supporting market plan



❖ **Total number of registrations** ❖
70

